Heat Biologics (NASDAQ: HTBX) is gaining 23% in pre-open trade after the company disclosed that in connection with the planned ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Heat Biologics (HTBX) Highlights Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology February 28, 2019 5:23 PM Form 8-K HEAT BIOLOGICS, INC. For: Feb 25February 25, 2019 5:03 PM